Association between ultrasonography screening and mortality in patients with hepatocellular carcinoma: a nationwide cohort study

Abstract

Shorter ultrasonography screening intervals are associated with reduced overall mortality in HCC patients in a dose-dependent manner.

Hepatocellular carcinoma is diagnosed at a later stage in alcoholic patients: Results of a prospective, nationwide study

“…10,11 Various assumptions can be made to explain why patients with alcohol-related HCC have reduced survival in comparison with patients with non-alcohol-related HCC: a diagnosis at a later stage due to lower rates of HCC screening, worse liver function and/or ongoing alcohol consumption preventing curative options, and discrimination against alcoholic patients leading to less aggressive treatment options. 18,[22][23][24][25] However, in our study, the rates of implementation of a cirrhosis follow-up program were comparable in the 2 groups (<30%) and could not per se explain the difference in survival between them. 21 Lack of a diagnosis of cirrhosis prevents the implementation of screening programs, which are associated with a diagnosis at an earlier stage, curative treatment, and improved survival.…”

Diabetes, hepatocellular carcinoma, and mortality in hepatitis C‐infected patients: A population‐based cohort study

“…The diagnosis of HCC was confirmed by linking with the Registry for Catastrophic Illness Patient Database, a subpart of the NHIRD, which was approved by the Bureau of National Health Insurance. The Registry for Catastrophic Illness Patient Database is supported by pathological reports and other supporting documents, such as laboratory and imaging studies . The date of death was defined as the date of death in the Catastrophic Illness Registry Data files, the date of discharge from insurance coverage within one month of being discharged as “critical and against medical advice,” or the date of discharge from insurance coverage within one month of discharge from an emergency department visit during which intravenous epinephrine was used.…”

Early diagnosis of liver cancer: an appraisal of international recommendations and future perspectives

“…Compared with the 6-months screened cohort, the adjusted hazards ratios of chance to receive curative therapy for the 24-months, 36-months and never screened cohorts were 0.73 (95% CI 0.69-0.78), 0.65 (95% CI 0.60-0.70) and 0.47 (95% CI 0.45-0.50) (all P < 0.001) respectively. However, the chance to receive curative therapy is not statistically different between the 6-months and 12-months cohorts (44).…”